A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE).
Matthew GumbletonStephanie AllanHannah ConwayKenneth M BoucherJames MarvinJosiah HawksWilliam BurnettMatthew Van BrocklinJonathan WhisenantGlynn GilcreaseSumati V GuptaPublished in: BMC research notes (2023)
Clinical trial registration number: NCT03407976. Date of registration: January 17, 2018.